Candesartan
| Evidence Level: L2 | Predicted Indications: 9 |
Table of Contents
Candesartan: Migraine disorder
One-Sentence Summary
Candesartan is an angiotensin II type 1 (AT1) receptor blocker that is currently marketed in Australia. The TxGNN model predicts it may be effective for migraine disorder, in particular migraine prevention. This direction is supported by 3 clinical trials directly studying migraine (two randomised, placebo-controlled trials and one observational study) and 20 publications, including a 2025 randomised trial in The Lancet Neurology.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9997 |
| Evidence Level | L2 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Candesartan blocks the angiotensin II type 1 receptor (gene AGTR1). Modulating the renin-angiotensin system is proposed to reduce migraine frequency through effects on cerebrovascular tone, neuroinflammation and sympathetic activity. Detailed mechanism-of-action data beyond this receptor-blocking role are not available in the data compiled for this report.
The prediction is supported by clinical work in migraine itself, not only by mechanism. A placebo-controlled, double-dummy trial compared candesartan with propranolol. A larger multicentre, triple-blind trial tested two doses (8 mg and 16 mg) against placebo. Its publication is a randomised trial in episodic migraine. A real-world Spanish observational study also examined response predictors and tolerability in patients who had failed several earlier preventive drugs.
An Australian review (Medical Journal of Australia, 2008) described the evidence for candesartan in migraine prophylaxis as “reasonably good but limited”. A 2025 scoping review and a systematic review of blood-pressure-lowering medicines for episodic migraine prevention also address this question.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT04574713 | Phase 2 | Completed | 450 | Multicentre, binational, triple-blind, placebo-controlled parallel-group trial of candesartan 8 mg and 16 mg for migraine prevention. It aimed to confirm the benefit of 16 mg seen in two smaller crossover studies, test whether 8 mg is effective, and confirm the side-effect profile. |
| NCT00884663 | Phase 2/3 | Completed | 72 | Double-blind, double-dummy, placebo-controlled triple crossover comparing candesartan with propranolol for migraine prophylaxis. The small sample limits statistical power. |
| NCT04138316 | N/A (observational) | Completed | 85 | Prospective, open, descriptive study of response predictors and tolerability of candesartan in adults with episodic or chronic migraine who had failed three or more preventive drugs. |
No ANZCTR identifiers were found in the data compiled for this report.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40975098 | 2025 | RCT | The Lancet Neurology | Randomised, triple-blind, placebo-controlled phase 2 trial evaluating the safety, tolerability and efficacy of candesartan for preventing episodic migraine. |
| 37350141 | 2023 | Systematic review and meta-analysis | Cephalalgia | Examines whether blood-pressure-lowering medicines beyond the few currently recommended agents help prevent episodic migraine. |
| 39899861 | 2025 | Clinical guideline | Annals of Internal Medicine | American College of Physicians guideline on pharmacological prevention of episodic migraine in outpatient settings. |
| 38057728 | 2023 | Systematic review and network meta-analysis | The Journal of Headache and Pain | Compares the effectiveness and ranking of preventive drugs for chronic migraine in adults. |
| 39365169 | 2024 | Systematic review | Health Technology Assessment | Compares clinical and cost-effectiveness of preventive drugs for chronic migraine. |
| 40571531 | 2025 | Scoping review | Clinical Therapeutics | Reviews candesartan, an angiotensin-receptor blocker, as a potential migraine treatment. |
| 38663908 | 2024 | Observational study | Cephalalgia | CandeSpartan study assessing the effectiveness, tolerability and response predictors of candesartan for migraine prevention. |
| 38307673 | 2024 | Book chapter (review) | Handbook of Clinical Neurology | Lists candesartan among non-specific oral agents for migraine prevention. |
| 18759728 | 2008 | Review | Medical Journal of Australia | Notes that evidence for candesartan in migraine prophylaxis is reasonably good but limited. |
| 34048395 | 2021 | Review | Continuum | Overview of preventive migraine treatment, including when to start and how to choose a therapy. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13436E | Atacand | Tablet containing candesartan cilexetil 8 mg (oral) | Not recorded in the data compiled for this report |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. No label-based warnings, contraindications or drug-interaction data were available in the data compiled for this report.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The evidence level is L2. Two randomised, placebo-controlled trials (a phase 2/3 crossover trial and a phase 2 parallel-group trial, the latter published in 2025) and a real-world observational study directly address migraine prevention. There are no multiple completed phase 3 trials, and the only listed Australian product is the 8 mg tablet.
To proceed, the following is needed:
- Review of the full results of NCT04574713 and PMID 40975098, including the efficacy of the 8 mg and 16 mg doses and their tolerability.
- Confirmation of whether a confirmatory phase 3 trial or independent replication is needed.
- Review of the TGA-approved PI for warnings, contraindications and interactions, which the data compiled for this report do not provide.
- A safety monitoring plan for patients who may be pregnant or have renal impairment, and for those taking other renin-angiotensin system agents.
- Clarification of dose and strength availability in Australia, since only an 8 mg tablet is listed locally.
- Detailed mechanism-of-action data linking AT1 receptor blockade to migraine prevention.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.